A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer ...

Former President Joe Biden, who was diagnosed with an aggressive form of prostate cancer in May, completed a course of ...

A spokesperson for Joe Biden says the former Democratic president has completed several weeks of radiation therapy to treat ...

Grape seed extract—a dietary supplement made from the seeds of wine grapes—has been investigated to see if it can help reduce ...

Dave Riley, from East Lancashire Prostate Cancer Support, said men over 50 can get tested annually, but "you can get checked ...

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

Combining 177 Lu-PSMA-617 with SOC produced statistically significant rPFS, reducing the risk of radiographic progression or death by 28% (HR 0.72; 95% CI, 0.58-0.90) vs SOC alone in patients with ...

In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis ...

When too much of it builds up, it can crystallize painfully in our joints, causing gout, or solidify into kidney stones. In ...

PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic ...

On-treatment PSA and disease burden should be considered together for prognostication. Achieving PSA ≤0.2 ng/mL within 6–12 weeks strongly predicts favorable long-term survival. Metastatic volume and ...